The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .
Bezafibrate Retard in Type II Diabetic Patients: Effects on Hemostasis and Glucose Homeostasis
A double-blind , placebo-controlled trial assessed the effect of a slow-release formulation of bezafibrate ( Bezalip Mono , 400 mg daily for 3 months ) on lipid profile , glucose homeostasis , platelet function , and plasma fibrinogen concentration in non-insulin-dependent ( type II ) diabetics . Twenty-four patients completed the trial . There was a significant improvement in the cholesterol ( p < 0.02 ) , triglyceride ( p < 0.01 ) , and nonesterified fatty acid ( p < 0.05 ) concentrations and in the fasting blood glucose ( p < 0.03 ) and glycosylated hemoglobin ( p < 0.01 ) levels of those ( n = 11 ) who received the active preparation but not in those ( n = 13 ) who received placebo . Treatment , but not placebo , also result ed in a significant ( p < 0.01 ) fall in plasma fibrinogen concentration and a trend towards inhibition of platelet aggregation .  Bezafibrate was well tolerated ; only one patient ( not included in the analysis of results ) withdrew from the trial possibly because of side effects of the drug . A larger study is needed to establish whether bezafibrate can reduce nonlipid risk factors ( e.g. , plasma fibrinogen concentration , glucose intolerance , and hyperinsulinemia ) in normo- and hyperlipidemic subjects
The observed effect was robust in sensitivity analyses and independent of fibrate dose .
The present meta- analysis suggests that fibrate therapy increases circulating levels of adiponectin .
BACKGROUND Several lines of evidence have indicated the insulin-sensitizing , anti-diabetic and anti-atherosclerotic properties of adiponectin , as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes .
Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy , but the findings have not been conclusive .
OBJECTIVE To systematic ally review and meta-analyze available evidence from r and omized placebo-controlled trials ( RCTs ) on the impact of fibrate therapy on circulating levels of adiponectin .